Skip to content

Author

E. Ammirati

We have 5 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Pathway in High-Risk Lymphocytic Acute Myocarditis

Background The programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway is affected in immune checkpoint inhibitor (ICI)-associated acute myocarditis (AM), while this pathway in non-ICI-associated lymphocytic AM (LAM) is unexplored. Objectives This study aimed to assess cardiac levels of PD-L1/PD-1...

E. Ammirati, G. Gallone, Giacomo Veronese et al. · 0 citations
Aug 2026

Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023.

The findings highlight the need for targeted strategies to improve early diagnosis and reduce the burden of myocarditis, particularly in vulnerable populations and lower-resource settings, while being interpreted in the context of evolving diagnostic and coding practices.

Sooji Lee, Hayeon Lee, Min Seo Kim et al. · 1 citation
Review Open access Oct 2026

A new Dawn: Advances and innovation in heart transplantation part I - cardiac magnetic resonance imaging in heart transplantation.

Heart transplantation (HTx) remains the treatment of choice for patients with advanced heart failure. HTx recipients require intensive surveillance over time. Major complications that should be monitored, prevented, and treated in a timely manner include graft dysfunction secondary to cellular rejection or antibody-med...

P. Sormani, E. Ammirati, A. Villaschi et al. · 0 citations
Open access Aug 2026

Pediatric extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: outcomes and clinical trajectories.

AIMS To characterize management, outcomes, and donation trajectories of pediatric extracorporeal cardiopulmonary resuscitation (ECPR) for out-of-hospital cardiac arrest (OHCA), and to describe early features observed among survivors and non-survivors. METHODS We conducted a retrospective single-centre observational c...

Giacomo Veronese, Lorenzo Grazioli, P. Meani et al. · 0 citations
Open access Aug 2026

Pattern of use of conventional medical treatments of heart failure with reduced ejection fraction in end-stage hypertrophic cardiomyopathy.

While BB and RASi are commonly used in ES-HCM, MRA and SGLT2i are prescribed less frequently and in patients with a worse clinical profile, suggesting both clinical inertia and limitations inherent to the disease pathophysiology.

G. Tini, Isabella Perlati, S. Palma et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.